
Riding the coattails of CAR-T cancer therapies, scientists have begun to explore a spin-off: using similar immune cells to treat autoimmune diseases such as type 1 diabetes and prevent rejection of transplanted organs.
In CAR-T therapies, T cells are extracted from a patient’s blood, reprogrammed to attack cancer cells, and then re-infused into the bloodstream to carry out their new assignment.